We are live on
!
Find out more
Arbutus Biopharma
ABUS
ABUS
11 hedge funds and large institutions have $6.09M invested in Arbutus Biopharma in 2013 Q2 according to their latest regulatory filings, with 11 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
11
Holders Change
+11
Holders Change %
–
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
Top Sellers
No sellers this quarter
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Bank of Montreal
Toronto,
Ontario, Canada
| $3.71M | +$3.74M | +789,828 | New |
|
|
PA
2
Perceptive Advisors
New York
| $1.24M | +$1.28M | +270,000 | New |
|
|
IGIM
3
I.G. Investment Management
Winnipeg,
Manitoba, Canada
| $691K | +$710K | +150,000 | New |
|
|
KA
4
Kerrisdale Advisers
Miami,
Florida
| $167K | +$168K | +35,560 | New |
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $88K | +$89.5K | +18,910 | New |
|
|
SKK
6
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| $82K | +$82.5K | +17,418 | New |
|
|
SIM
7
Spark Investment Management
New York
| $59K | +$60.1K | +12,700 | New |
|
|
FANJ
8
Financial Architects (New Jersey)
Marlton,
New Jersey
| $42K | +$42.6K | +9,000 | New |
|
9
Wells Fargo
San Francisco,
California
| $1K | +$947 | +200 | New |
|
10
Barclays
London,
United Kingdom
| $1K | +$1.42K | +300 | New |
|
11
Citigroup
New York
| – | +$95 | +20 | New |
|
ABUS Hedge Fund Activity: Q2 2013 in Review
11 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2013, worth a combined $6.09M.
Buyers outnumbered sellers: 11 funds opened new ABUS positions and 0 closed out — a net gain of 11 holders — while 0 added to existing stakes and 0 trimmed.
- 11 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $6.09M of Arbutus Biopharma stock for Q2 2013.
- 11 funds opened new Arbutus Biopharma positions in Q2 2013 and 0 closed out, a net change of +11 holders.
Based on aggregated 13F filings for Q2 2013.